Aerie Pharmaceuticals (AERI) Receives Daily Coverage Optimism Score of 0.27

News stories about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.3769069395789 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern’s rankings:

AERI has been the subject of a number of research analyst reports. Guggenheim initiated coverage on Aerie Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $80.00 target price for the company. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Mizuho reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, November 3rd. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company’s stock. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $72.00.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at $59.35 on Friday. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $2,180.00, a PE ratio of -17.72 and a beta of 1.11. Aerie Pharmaceuticals has a 52-week low of $37.80 and a 52-week high of $66.60.

TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply